PH Grants Emergency Use of Authorization for Sinovac Vaccine

The Philippine Food and Drug Administration (FDA) has granted the Emergency Use of Authorization (EUA) for the China-based Sinovac COVID-19 Vaccine for the country’s national vaccination program set to roll out this month.

This was announced by FDA Director-General Dr. Eric Domingo today, February 22, 2021 (Monday), during the Laging Handa Public Briefing.

Furthermore, it was stated by Domingo that it was shown in the ongoing Phase 3 trial of Sinovac that it has an efficacy of 65.3 to 91.2 percent after the first dose when used on clinically healthy members of the community age 18 to 59.

“It is decided that all conditions for an EUA are present and that the benefit of using the vaccine outweighs the known potential risks. The interim data from the ongoing Phase 3 trial shows that when the vaccine is used on clinically healthy members of the community age 18 to 59, it has an efficacy of 65.3 to 91.2 percent after the first dose.”
-FDA Director General Domingo  | PNA

In addition, the 65.3 efficacy rate was seen in Indonesia and the efficacy rate 91.2 was in Turkey according to Domingo.
Domingo added that the Sinovac vaccine when used on healthcare workers exposed to coronavirus has a lower efficacy rate of 50.4 percent. Thus, it is not recommended for use to the said group.

Related Articles:

Pfizer and BioNTech Announced Start of Trial of COVID-19 Vaccine in Pregnant Women

WHO Approves AstraZeneca Vaccine for Emergency Use

3 Vaccines Granted EUA in PH

These are now the three coronavirus vaccines granted EUA in the country:

Conditions for Issuance of EUA

Under Executive Order No. 121, EUA on coronavirus drug or vaccine shall be issued and remain valid only when the following are present:

  • Based on the totality of evidence available, including data from adequate and well-known controlled trials, it is reasonable to believe that the drug or vaccine may be effective to prevent, diagnose or treat COVID-19.
  • The known and potential benefits of the drug or vaccine when used to diagnose, prevent or treat COVID-19 outweigh the known and potential risks of the drug or vaccine if any.
  • There is no adequate, approved, and available alternative to the drug or vaccine for diagnosing, preventing, or treating COVID-19.

Related Articles:

Pfizer’s Vaccine Shows Promising Results in Israel, Says Report

DOH, FDA, and NTF Warn Public Against People Claiming to Offer COVID-19 Vaccines

For More News and Updates

Looking for more news and updates? Feel free to explore our BCG website and our official Facebook page. You may also check out our official BCG YouTube channel to catch a variety of video content.

How do you feel about this?

Not Sure

You may also like

Leave a reply